HDAC1-IN-3

HDAC1-IN-3 (compound JX35) shows antimalarial activity with IC₅₀s of 1.26 nM and 1.61 nM for wild-type Plasmodium falciparum (P. falciparum) parasite 3D7 and chloroquine-resistant P. falciparum parasite Dd2, respectively^[1].
HDAC1-IN-3 (10 µM; 72 h) shows low cytotoxicity with IC₅₀s of 1.02 µM and 1.21 µM for HepG2, 293T cells, respectively^[1].
HDAC1-IN-3 (72 h) shows no cross-resistance with clinical antimalarial drugs with IC₅₀s of 3.06, 2.18, 5.85 nM for GB4, C2A, CP286, respectively^[1].
HDAC1-IN-3 (10, 30, 60, 100 nM; 3, 6, 12, 24 h) shows antimalarial activity in a time- and dose-dependent manner with asynchronous 3D7 parasites^[1].
HDAC1-IN-3 (40 nM, 4 days; P. falciparum 3D7 cells) shows the killing effects of JX35 on P. falciparum parasites during asexual reproduction stages might be related to the inhibition of schizont growth and reinvasion of RBCs (red blood cells)^[1].
HDAC1-IN-3 (5, 20 nM; 4 h) inhibits the expression of Pf HDAC against ART (artemisinin)-resistant parasite strains^[1].
HDAC1-IN-3 reduces the inhibition of hHDACs with IC₅₀s of 2.2, 5.1, 5.2, 85.5, 29.9 nM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.